Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702Akira Inoue, Toshihiro Nukiwa, Hiroshi Watanabe et al.|Lung Cancer|2015Cited by 35
Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL StudyRyota Saito, Kunihiko Kobayashi, Shunichi Sugawara et al.|European Journal of Cancer|2023Cited by 27
Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M MutationKana Watanabe, Makoto Maemondo, Eisaku Miyauchi et al.|Cancers|2023Cited by 9
Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601)Atsushi Nakamura, Shunichi Sugawara, Hisashi Tanaka et al.|The Oncologist|2020Cited by 6
Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802Yosuke Kawashima, Toshihiro Nukiwa, Akira Inoue et al.|Respiratory Investigation|2014Cited by 3